to compare the effects of acotiamide on symptom profile and gastric emptying time with domperidone in diabetic gastroparesis: a double blind randomised control trial’

Treatment with either drug is going to improve blood sugar levels and quality of life in diabetic patients

Patients will be regularly followed up during their one month therapy with either drug. Appearance of any untoward side effect will be taken into serious consideration. Patients will have the liberty to withdraw from the trial at any time.

At the end of one month therapy with either drug, patients will have to undergo repeat evaluation of gastric emptying time, small bowel transit time, gastric antral volume, gall bladder ejection fraction by the same aforementioned methods for comparison of the effects of the drugs.

Previous literature has shown the efficacy of Domperidone in diabetic gastroparesis without any serious side effect.

On the other hand, randomized control trials involving Acotiamide have shown promising results in functional dyspepsia without any significant side effect. Adequate trials in diabetic gastroparesis are awaited.

Assessment  and treatment of diabetic patient for gastroparesis is going to improve there quality of life and blood glucose control, So gastroparesis  requires pharmaceutical interventions for improvement of symptom profile and quality of life

Drugs available for gastroparesis have limited efficacy  ,tachyphylaxis (decreasing response with continued use )  ,and high rate of side effect profile .So there is urgent need of some novel drug bypassing all these limitations . So, if results of Acotiamide are found to be significantly beneficial in our trial, then it can be subjected to further analysis and it may be favourable for the population at large.